TWI775333B - 治療癌症之方法 - Google Patents

治療癌症之方法 Download PDF

Info

Publication number
TWI775333B
TWI775333B TW110107282A TW110107282A TWI775333B TW I775333 B TWI775333 B TW I775333B TW 110107282 A TW110107282 A TW 110107282A TW 110107282 A TW110107282 A TW 110107282A TW I775333 B TWI775333 B TW I775333B
Authority
TW
Taiwan
Prior art keywords
cancer
administered
period
day
inhibitor
Prior art date
Application number
TW110107282A
Other languages
English (en)
Chinese (zh)
Other versions
TW202146025A (zh
Inventor
凱倫 蘇 布哈納
煜輝 黃
Original Assignee
美商亞雷生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商亞雷生物製藥股份有限公司 filed Critical 美商亞雷生物製藥股份有限公司
Publication of TW202146025A publication Critical patent/TW202146025A/zh
Application granted granted Critical
Publication of TWI775333B publication Critical patent/TWI775333B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW110107282A 2020-03-03 2021-03-02 治療癌症之方法 TWI775333B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062984458P 2020-03-03 2020-03-03
US62/984,458 2020-03-03
US202163133501P 2021-01-04 2021-01-04
US63/133,501 2021-01-04

Publications (2)

Publication Number Publication Date
TW202146025A TW202146025A (zh) 2021-12-16
TWI775333B true TWI775333B (zh) 2022-08-21

Family

ID=74860342

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110107282A TWI775333B (zh) 2020-03-03 2021-03-02 治療癌症之方法
TW111128154A TWI814504B (zh) 2020-03-03 2021-03-02 治療癌症之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111128154A TWI814504B (zh) 2020-03-03 2021-03-02 治療癌症之方法

Country Status (12)

Country Link
US (1) US20230117328A1 (enExample)
EP (1) EP4114397A1 (enExample)
JP (2) JP7181325B2 (enExample)
KR (1) KR20220148867A (enExample)
CN (1) CN115529816A (enExample)
AU (1) AU2021231435A1 (enExample)
BR (1) BR112022017267A2 (enExample)
CA (1) CA3174064A1 (enExample)
IL (1) IL296060A (enExample)
MX (1) MX2022010955A (enExample)
TW (2) TWI775333B (enExample)
WO (1) WO2021176330A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023002360A1 (en) * 2021-07-22 2023-01-26 Pfizer Inc. Solid forms and formulations of an inhibitor of tam and c-met kinases
CN122140719B (zh) * 2026-04-15 2026-07-28 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Sgi-7079在治疗flt3突变型急性髓系白血病中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209457A1 (en) * 2014-07-31 2017-07-27 Novartis Ag Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2016019270A1 (en) 2014-07-31 2016-02-04 Academia Sinica An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209457A1 (en) * 2014-07-31 2017-07-27 Novartis Ag Combination Therapy

Also Published As

Publication number Publication date
CN115529816A (zh) 2022-12-27
TW202317125A (zh) 2023-05-01
JP2023009250A (ja) 2023-01-19
TWI814504B (zh) 2023-09-01
BR112022017267A2 (pt) 2022-12-13
WO2021176330A1 (en) 2021-09-10
IL296060A (en) 2022-10-01
AU2021231435A1 (en) 2022-09-22
MX2022010955A (es) 2022-10-07
JP2021138693A (ja) 2021-09-16
EP4114397A1 (en) 2023-01-11
JP7181325B2 (ja) 2022-11-30
US20230117328A1 (en) 2023-04-20
TW202146025A (zh) 2021-12-16
CA3174064A1 (en) 2021-09-10
KR20220148867A (ko) 2022-11-07

Similar Documents

Publication Publication Date Title
TWI607754B (zh) 醫藥組合
JP6449234B2 (ja) 併用療法
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
KR102439911B1 (ko) 제약학적 복합제제
BR112019021880A2 (pt) Terapia de combinação com conjugado anticorpo anti-axl-droga
CN114945369A (zh) 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法
JP2020517652A5 (enExample)
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
TWI814504B (zh) 治療癌症之方法
Konar et al. Synthesis and clinical development of palbociclib: An overview
JP2026501925A (ja) Ｈｅｒ２阻害剤の固体分散剤の投与スケジュール
HK40079302A (en) Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
US20230340136A1 (en) Treatment of cll
WO2024263960A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer
WO2026103822A1 (zh) Ras抑制剂和pd-1或pd-l1抑制剂的组合及其用途
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
EA045355B1 (ru) Комбинированная терапия конъюгатом анти-axl антитело-лекарственное средство

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees